Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer

Cancer Control

Volumn 16, Issue 2, 2009, Pages 176-185

  Holmes, Laurens ^a,d,e   Chan, Wenyaw ^c   Jiang, Zhidong ^b   Ward, Doriel ^b   Essien, James ^e   Du, Xianglin L ^b  

^a Nemours Center   (Sweden)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF DELAWARE   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

AFRICAN AMERICAN; AGED; AGING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASIAN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; ETHNICITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH CARE DISPARITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORCHIECTOMY; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 65249149628     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600210     Document Type: Article

References (70)

1. Miller BA, Kolonel LN, Bernstein L, et al. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. NIH Pub. No. 96-4104. Bethesda, MD: National Cancer Institute; 1996. hrttp://seer.cancer.gov/publications/ ethnicity/index.html. Accessed January 30, 2009.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute; 2002. hrttp://seer.cancer. gov/csr/1973-1999/. Accessed December 9, 2008.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30.
4. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men in the United States. Cancer. 2003;97(6):1507-1516.
5. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda, MD, 1999.
6. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med. 2002;162(17):1985-1993.
7. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93(5):388-395.
8. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13(1):93-100.
9. Morton RA Jr. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994;44(5):637-645.
10. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793-803.
11. Wingo PA, Bolden S, Tong T, et al. Cancer statistics for African Americans, 1996. CA Cancer J Clin. 1996;46(2):113-125. Erratum in: CA Cancer J Clin. 1996;46(3):164.
12. Dayal HH, Chiu C. Factors associated with racial differences in survival for prostatic carcinoma. J Chronic Dis. 1982;35(7):553-560.
13. Bennett CL, Price DK, Kim S, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20(17):3599-3604.
14. Witte JS, Nelson KA. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002;155(10):883-890.
15. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64(6):1171-1176.
16. Yan Y, Carvalhal GF, Catalona WJ, et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88(5):1122-1130.
17. Vijayakumar S, Weichselbaum R, Vaida F, et al. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996;2(4):225-233.
18. Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer. 1998;83(2):320-330.
19. Demers RY, Tiwari A, Wei J, et al. Trends in the utilization of andro-gen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001;92(9):2309-2317.
20. Fowler JE Jr, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol. 1996;156(1):133-136.
21. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006;106(6):1276-1285.
22. Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc. 1998;90(2):101-104.
23. Conlisk EA, Lengerich EJ, Demark-Wahnefried W, et al. Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. Urology. 1999;53(6):1194-1199.
24. Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56(6):1016-1020.
25. Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993; 71(8):2569-2573.
26. Optenberg SA, Thompson IM, Friedrichs P, et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274(20):1599-1605.
27. Denberg TD, Beaty BL, Kim FJ, et al. Marriage and ethnicity predict treatment in localized prostate carcinoma. Cancer. 2005;103(9):1819-1825.
28. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31(8):732-748.
29. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-18.
30. Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer. 2002;95(7):1401-1414.
31. National Cancer Institute. SEER-Medicare Linked Database. http:// healthservices.cancer.gov/seermedicare. Accessed December 10, 2008.
32. Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19(5):1455-1461.
33. Du XL, Key CR, Dickie L, et al. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44(2):124-131.
34. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol. 1999;52(5):463-470.
35. Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005;104(5):913-924.
36. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
37. Kleinbaum DG, Klein M, eds. Survival Analysis: A Self-Learning Text. New York, NY: Springer Science + Business Media, Inc; 1996.
38. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int. 2001;87(9):806-813.
39. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78-93.
40. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13(1):93-100.
41. Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36(9):1337-1348.
42. Imperato PJ, Nenner RP, Will TO. Radical prostatectomy: lower rates among African-American men. J Natl Med Assoc. 1996;88(9):589-594.
43. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996; 34(2):152-162.
44. Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19(2):146-155.
45. Burns RB, McCarthy EP, Freund KM, et al. Black women receive less mammography even with similar use of primary care. Ann Intern Med. 1996; 125(3):173-182.
46. Steginga SK, Occhipinti S, Gardiner RA, et al. Making decisions about treatment for localized prostate cancer. BJU Int. 2002;89(3):255-260.
47. Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. Arch Intern Med. 2002;162(21):2458-2463.
48. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283(24):3217-3222.
49. Feldman-Stewart D, Brundage MD, Hayter C, et al. What prostate cancer patients should know: variation in professionals' opinions. Radiother Oncol. 1998;49(2):111-123.
50. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341(16):1198-1205.
51. Akaza H. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int. 2004;93(1):42-46.
52. Koff SG, Connelly RR, Bauer JJ, et al. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. Prostate Cancer Prostatic Dis. 2002;5(2):152-158.
53. Wang Y, Sudilovsky D, Zhang B, et al. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res. 2001;61(16):6064-6072.
54. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000;(27):39-66.
55. Wu AH, Whittemore AS, Kolonel LN, et al. Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men. Cancer Epidemiol Biomarkers Prev. 2001;10(5):533-538.
56. Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92(24):2009-2017.
57. Kubricht WS III, Williams BJ, Whatley T, et al. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54(6):1035-1038.
58. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16): 1118-1126.
59. Heikkilä R, Aho K, Heliövaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999;86(2):312-315.
60. Thatai LC, Banerjee M, Lai Z, et al. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology. 2004;64(4):738-743.
61. Horner RD. Racial variation in cancer care: a case study of prostate cancer. Cancer Treat Res. 1998;97:99-114.
62. Tewari A, Horninger W, Pelzer AE, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int. 2005;96(9):1247-1252.
63. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer. 1992;70(8):2152-2158.
64. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol. 2000;151(4):409-416.
65. Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95(22):1702-1710.
66. Giovannucci E, Rimm EB, Wolk A, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 1998;58(3):442-447.
67. Kienta KJ, Demers R, Hoff M, et al. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology. 1995;45(1):93-101; discussion 101-102.
68. Roach M III, Lu J, Pilepich MV, et al. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003;169(1):245-250.
69. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol. 1998;148(5):475-486.
70. Holmes L Jr, Chan W, Jiang Z, et al. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(4):388-395. Epub 2007 May 8.